| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and collaboration revenue | 795 | 1,497 | 858 | - |
| Research and development | 9,356 | 10,343 | 10,146 | 9,702 |
| General and administrative | 4,596 | 4,182 | 3,812 | 3,814 |
| Impairment of right-of-use asset | 494 | - | - | - |
| Total operating expenses | 14,446 | 14,525 | 13,958 | 13,516 |
| Loss from operations | -13,651 | -13,028 | -13,100 | -13,516 |
| Other nonoperating expense | - | - | - | 62 |
| Interest income | 423 | 453 | 588 | 94 |
| Change in fair value of derivative tranche liability | -1,800 | - | - | - |
| Other expense | -71 | -12 | 79 | - |
| Total other (expense) income, net | -1,448 | 441 | 667 | 32 |
| Net loss attributable to common stockholders | -15,099 | -12,587 | -12,433 | -13,484 |
| Comprehensive loss | -15,099 | -12,587 | -12,433 | -13,484 |
| Net loss per share attributable to common stockholders, basic, (in dollars per share) | -0.55 | -0.62 | -0.62 | -24.19 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.55 | -0.62 | -0.62 | -24.19 |
| Weighted-average common shares outstanding, diluted (in shares) | 27,274,721 | 20,159,666 | 20,152,872 | 557,437 |
| Weighted-average shares of common stock outstanding, basic (in shares) | 27,274,721 | 20,159,666 | 20,152,872 | 557,437 |
Camp4 Therapeutics Corp (CAMP)
Camp4 Therapeutics Corp (CAMP)